ADMINISTRATIVE CORE

行政核心

基本信息

  • 批准号:
    7283873
  • 负责人:
  • 金额:
    $ 45.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-04-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

ADMINISTRATIVE COMPONENT: Director - M. Lazar The Administrative Component of the Penn DERC is led by Center Director, Dr. Mitchell A. Lazar. Dr. Morris J. Birnbaum serves as Associate Director and designated interim replacement DERC director, and Dr. Karen Teff is Assistant Director for Translational Research. This component bears the responsibility for organizing, carefully overseeing, and continuously evaluating the quality of the scientific cores for the benefit of the Center investigators in strict observance of the Guidelines issued by the NIDDK for the operation of Diabetes, Endocrinology Research Centers. The Administrative Component also oversees a highly successful Pilot and Feasibility Grant Program as well as an Academic Enrichment Program whose activities include a weekly research lecture series, several monthly workgroup meetings highlighting interactive and translational research focused on obesity, cardiovascular complications, and patient-oriented research, and an annual Spring Diabetes Symposium featuring an expansive poster session, lectures by selected Penn DERC faculty, and the Kroc Lecture. The Director and Associate Director are aided in their task by several standing advisory and oversight groups. These include the Executive Committee, which at present consists of Drs. Kaestner, Matschinsky, Stanley, Wolf, and Naji in addition to Drs. Lazar, Birnbaum, and Teff; the Committee of Core Directors; an External Advisory Board, consisting of leaders in the field of Diabetes and Metabolism; and an Internal Advisory Board, consisting of key scientific leaders at Penn who are not in administrative positions in the DERC but function as Department Chairs, Center Directors, and Core Directors. The activities of the DERC are also thoroughly reviewed periodically by the University of Pennsylvania School of Medicine, and have strong institutional support. By coordinating and integrating all diabetes related activities of the Center and its investigators, the Administrative Component plays an indispensable role in facilitating inter-disciplinary Diabetes-related research and research training.
行政部门:主任- M。拉扎尔 宾夕法尼亚大学DERC的行政部门由中心主任米切尔博士领导。拉扎尔 博士Morris J. Birnbaum担任副主任,并被指定为DERC的临时替代者 主任,和博士卡伦Teff是助理主任转化研究。此组件 负责组织、仔细监督和持续评估 为了中心研究人员的利益,严格遵守 NIDDK发布的糖尿病内分泌研究中心操作指南。 行政部门还监督一项非常成功的试点和可行性赠款 计划以及学术充实计划,其活动包括每周研究 讲座系列,几个月的研讨会,强调互动和翻译 研究重点是肥胖、心血管并发症和以患者为导向的研究, 一年一度的春季糖尿病研讨会设有一个广阔的海报会议,讲座由选定的 Penn DERC教师和Kroc讲座。主任和副主任在工作中得到协助, 由几个常设咨询和监督小组执行。其中包括执行委员会, 目前由Kaestner博士、Matschinsky博士、Stanley博士、Wolf博士和Naji博士组成。 Lazar,Birnbaum和Teff;核心董事委员会;外部咨询委员会, 由糖尿病和代谢领域的领导者组成;和一个内部咨询委员会, 由宾夕法尼亚大学的主要科学领导人组成,他们不在DERC担任行政职务, 担任部门主席、中心主任和核心主任。DERC的活动 宾夕法尼亚大学医学院也定期进行全面审查, 并有强大的制度支持。通过协调和整合所有糖尿病相关活动 在中心及其调查人员中,行政部门发挥着不可或缺的作用, 促进跨学科的糖尿病相关研究和研究培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MITCHELL A. LAZAR其他文献

MITCHELL A. LAZAR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MITCHELL A. LAZAR', 18)}}的其他基金

PPARa and related nuclear receptors in non-alcoholic fatty liver disease
PPARa 和相关核受体在非酒精性脂肪肝中的作用
  • 批准号:
    10210669
  • 财政年份:
    2021
  • 资助金额:
    $ 45.01万
  • 项目类别:
PPARa and related nuclear receptors in non-alcoholic fatty liver disease
PPARa 和相关核受体在非酒精性脂肪肝中的作用
  • 批准号:
    10372221
  • 财政年份:
    2021
  • 资助金额:
    $ 45.01万
  • 项目类别:
PPARa and related nuclear receptors in non-alcoholic fatty liver disease
PPARa 和相关核受体在非酒精性脂肪肝中的作用
  • 批准号:
    10576286
  • 财政年份:
    2021
  • 资助金额:
    $ 45.01万
  • 项目类别:
Thyroid hormone receptors - regulation and function
甲状腺激素受体 - 调节和功能
  • 批准号:
    8010993
  • 财政年份:
    2010
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genome-wide epigenetic control of circadian metabolism by heme receptor Rev-erb
血红素受体 Rev-erb 对昼夜节律代谢的全基因组表观遗传控制
  • 批准号:
    7817388
  • 财政年份:
    2009
  • 资助金额:
    $ 45.01万
  • 项目类别:
Univ of Pennsyvania Diabetes Endocrinology Res Ctr
宾夕法尼亚大学糖尿病内分泌研究中心
  • 批准号:
    7980511
  • 财政年份:
    2009
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genome-wide epigenetic control of circadian metabolism by heme receptor Rev-erb
血红素受体 Rev-erb 对昼夜节律代谢的全基因组表观遗传控制
  • 批准号:
    7934606
  • 财政年份:
    2009
  • 资助金额:
    $ 45.01万
  • 项目类别:
Nuclear Receptor Coregulator Functional Pathology in Metabolic Disease
代谢性疾病中的核受体共调节功能病理学
  • 批准号:
    7350615
  • 财政年份:
    2007
  • 资助金额:
    $ 45.01万
  • 项目类别:
ROLE OF RESISTIN IN INSULIN RESISTANCE
抵抗素在胰岛素抵抗中的作用
  • 批准号:
    7486267
  • 财政年份:
    2007
  • 资助金额:
    $ 45.01万
  • 项目类别:
Differentiated funtion of tissues involved in nutrition and metabolism
参与营养和代谢的组织的分化功能
  • 批准号:
    7499959
  • 财政年份:
    2007
  • 资助金额:
    $ 45.01万
  • 项目类别:

相似海外基金

The Role of CA8 in Hepatic Glucose Production and Its Prospect as Type 2 Diabetes Mellitus Treatment
CA8在肝葡萄糖生成中的作用及其治疗2型糖尿病的前景
  • 批准号:
    24K19287
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic efficacy of dapagliflozin, a selective inhibitor of sodium–glucose co-transporter type 2, for chronic heart failure in Japanese patients with type 2 diabetes mellitus
选择性钠抑制剂达格列净的治疗效果
  • 批准号:
    23K06224
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Community-based Preconception Lifestyle Intervention to prevent Gestational Diabetes Mellitus in Women living in India
以社区为基础的孕前生活方式干预,以预防印度妇女妊娠期糖尿病
  • 批准号:
    494564
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Operating Grants
Linoleic acid-derived oxylipin species and cognitive function in type 2 diabetes mellitus
亚油酸衍生的氧脂素种类与 2 型糖尿病的认知功能
  • 批准号:
    495437
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
Pathophysiological analysis of the beta cell volume change elicited by pregnancy and gestational diabetes mellitus in Japanese pregnant women
日本孕妇妊娠和妊娠糖尿病引起的β细胞体积变化的病理生理学分析
  • 批准号:
    23K08020
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The role of CXCL10-CXCR3 axis in the compounding effects of diabetes mellitus in periodontitis
CXCL10-CXCR3轴在糖尿病牙周炎复合作用中的作用
  • 批准号:
    10740433
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
The Study of the Association between Gestational Diabetes Mellitus and Mental Health during Pregnancy in Japanese Women
日本女性妊娠期糖尿病与孕期心理健康关系的研究
  • 批准号:
    23K10101
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized diet therapy useful for glycemic control and quality of life in patients with type 1 diabetes mellitus
个性化饮食疗法有助于 1 型糖尿病患者的血糖控制和生活质量
  • 批准号:
    23K10809
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidating the Pathophysiology of Gestational Diabetes Mellitus
阐明妊娠糖尿病的病理生理学
  • 批准号:
    10738361
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了